MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
LIPO Lipella Pharmaceuticals
- 2.610
- +0.040+1.56%
Close Dec 20 16:00 ET
- 2.660
- +0.050+1.92%
Post 20:01 ET
3.16MMarket Cap-0.61P/E (TTM)
2.760High2.570Low58.91KVolume2.600Open2.570Pre Close156.31KTurnover6.90%Turnover RatioLossP/E (Static)1.21MShares12.00052wk High2.16P/B2.23MFloat Cap2.21052wk Low--Dividend TTM853.80KShs Float61.760Historical High--Div YieldTTM7.39%Amplitude2.210Historical Low2.653Avg Price1Lot Size
Lipella Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 5.26%-653.1K | -40.15%-918.14K | -28.86%-1.39M | -72.03%-3.15M | -214.27%-727.71K | -115.28%-689.36K | -12.96%-655.11K | -54.12%-1.08M | -85.10%-1.83M | 50.85%-231.56K |
| Net income from continuing operations | -9.15%-1.44M | 39.03%-938.15K | -11.61%-1.19M | -77.81%-4.62M | -89.29%-688.88K | -85.43%-1.32M | -96.76%-1.54M | -44.70%-1.07M | -39.25%-2.6M | 5.40%-363.93K |
| Depreciation and amortization | -24.95%722 | --1.37K | --72 | --1.69K | --723 | --962 | --0 | --0 | --0 | --0 |
| Other non cash items | ---3 | ---649 | 3,619.86%200.65K | 1,160.92%121.2K | --0 | ---- | ---- | 233.37%5.39K | 40.65%9.61K | 174.29%4.7K |
| Change In working capital | 92.88%411.39K | -250.01%-62.03K | -170.29%-605.99K | -195.64%-9.11K | -130.98%-39.55K | 128.93%213.29K | 416.57%41.35K | -13.09%-224.2K | -95.18%9.52K | 509.76%127.66K |
| -Change in prepaid assets | 851.32%163.84K | -114.76%-22.13K | -488.96%-733.6K | 197.97%460.63K | 243.76%104.82K | 113.01%17.22K | 201.78%149.98K | 185.35%188.61K | -571.10%-470.18K | 142.31%30.49K |
| -Change in payables and accrued expense | 9.08%243.73K | 55.30%-73.54K | 137.08%164.04K | -192.59%-548.86K | -178.41%-165.33K | -0.92%223.44K | -222.66%-164.52K | -2,082.16%-442.46K | 201.30%592.82K | 419.24%210.86K |
| -Change in other current assets | 81.37%-425 | 215.15%38 | 729.41%214 | -518.03%-2.25K | 391.18%99 | -22,710.00%-2.28K | -118.44%-33 | -108.44%-34 | -71.43%538 | -111.22%-34 |
| -Change in other working capital | 116.95%4.25K | -39.91%33.6K | -223.44%-36.65K | 171.59%81.37K | --20.85K | ---25.1K | --55.92K | --29.69K | -264.63%-113.66K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 5.26%-653.1K | -40.25%-918.79K | -28.80%-1.39M | -72.03%-3.15M | -214.27%-727.71K | -115.28%-689.36K | -12.96%-655.11K | -54.12%-1.08M | -85.10%-1.83M | 50.85%-231.56K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -104.80%-14.43K | 0 | 200.00%300.55K | 0 | ||||||
| Net PPE purchase and sale | ---- | ---- | ---- | ---14.43K | --0 | ---- | ---- | ---- | --0 | ---- |
| Net investment purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | 200.00%300.55K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---- | ---- | ---- | -104.80%-14.43K | --0 | ---- | ---- | ---- | 200.00%300.55K | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 820.33K | 0 | 900.00%200K | -74.49%1.34M | -69.24%1.61M | 0 | -250K | -25K | 149.82%5.24M | 233,138.20%5.24M |
| Net issuance payments of debt | --0 | --0 | --0 | -200.00%-275K | --0 | --0 | ---250K | ---25K | --275K | --275K |
| Net common stock issuance | --820.33K | --0 | --200K | --0 | --0 | --0 | --0 | --0 | 136.71%4.96M | ---- |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | --1.61M | ---- | ---- | ---- | ---- | --0 | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --820.33K | --0 | 900.00%200K | -74.49%1.34M | -69.24%1.61M | --0 | ---250K | ---25K | 149.82%5.24M | 233,138.20%5.24M |
| Net cash flow | ||||||||||
| Beginning cash position | -61.89%1.19M | -47.61%2.11M | -35.69%3.29M | 262.26%5.12M | 1,999.68%2.41M | 615.81%3.11M | 869.77%4.02M | 262.26%5.12M | 133.02%1.41M | -94.74%114.77K |
| Current changes in cash | 123.76%167.23K | -1.51%-918.79K | -7.75%-1.19M | -149.30%-1.83M | -82.35%883.89K | -119.79%-703.8K | -4,497.79%-905.11K | -10.36%-1.1M | 359.42%3.71M | 750.70%5.01M |
| End cash Position | -43.82%1.35M | -61.89%1.19M | -47.61%2.11M | -35.69%3.29M | -35.69%3.29M | 1,999.68%2.41M | 615.81%3.11M | 869.77%4.02M | 262.26%5.12M | 262.26%5.12M |
| Free cash flow | 7.20%-653.1K | -40.25%-918.79K | -28.80%-1.39M | -72.82%-3.16M | -214.27%-727.71K | -119.79%-703.8K | -12.96%-655.11K | -54.12%-1.08M | -85.10%-1.83M | 50.85%-231.56K |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.